Analyst firms · UBS · MRNA

UBS MRNA price target and rating history

Moderna Inc. (MRNA) · Health Care

UBS rates Moderna Inc. (MRNA) Neutral with a $34 price target, as of its latest action on Jan 7, 2026. It has published 3 rating actions on MRNA since January 2022, including 1 upgrade and 0 downgrades. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57. UBS's $34 is 40% below that.

Current rating

Neutral

Price target

$34

Median target, all firms

$57

Actions on MRNA

3

UBS price target on MRNA

Every UBS rating on MRNA

• Jan 7, 2026
  ResumeUBS resumes coverage at Neutral, price target $34
• Jun 26, 2023
  UpgradeUBS upgrades to Buy from Neutral, price target $221 to $191
• Jan 21, 2022
  InitiateUBS starts coverage at Neutral, price target $221

How other firms rate MRNA

Each firm's latest rating and stated target in the last 12 months.

Questions about UBS and MRNA

What is UBS's price target for MRNA?

UBS's latest stated price target for Moderna Inc. (MRNA) is $34, from its action on Jan 7, 2026.

What is UBS's rating on MRNA?

UBS rates MRNA Neutral, a neutral rating, as of Jan 7, 2026.

When did UBS last change its view on MRNA?

On Jan 7, 2026, UBS resumes coverage at Neutral, price target $34.

How does UBS's MRNA target compare with other analysts?

Across 6 firms with a MRNA price target in the last 12 months, the median target is $57. UBS's $34 is 40% below that.

More MRNA rating histories

• William Blair3
• Argus Research3
• Wolfe Research3
• BofA Securities3
• Barclays4
• Jefferies5
• HSBC5
• Oppenheimer3
• Deutsche Bank7
• TD Cowen4
• Leerink Partners5
• Morgan Stanley5
• Piper Sandler3

All UBS ratingsMRNA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.